Lyell Immunopharma Inc [LYEL] stock prices are up 16.63% to $1.12 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LYEL shares have gain 20.82% over the last week, with a monthly amount drifted -5.88%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lyell Immunopharma Inc [NASDAQ: LYEL] stock has seen the most recent analyst activity on October 30, 2024, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $1 from $6. Previously, H.C. Wainwright downgraded its rating to Neutral on June 27, 2024, and dropped its price target to $1. On August 28, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $7 on November 14, 2022. Goldman downgraded its rating to a Neutral and reduced its price target to $7 on November 11, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on October 17, 2022, and assigned it a price target of $12. In a note dated July 12, 2021, Morgan Stanley initiated an Overweight rating and provided a target price of $25 on this stock.
The stock price of Lyell Immunopharma Inc [LYEL] has been fluctuating between $0.85 and $3.26 over the past year. Currently, Wall Street analysts expect the stock to reach $6.67 within the next 12 months. Lyell Immunopharma Inc [NASDAQ: LYEL] shares were valued at $1.12 at the most recent close of the market. An investor can expect a potential return of 495.54% based on the average LYEL price forecast.
Analyzing the LYEL fundamentals
The Lyell Immunopharma Inc [NASDAQ:LYEL] reported sales of 0.05M for trailing twelve months, representing a drop of -51.85%. Gross Profit Margin for this corporation currently stands at -370.96% with Operating Profit Margin at -4227.89%, Pretax Profit Margin comes in at -3893.69%, and Net Profit Margin reading is -3893.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.33 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9829 points at the first support level, and at 0.8457 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2186, and for the 2nd resistance point, it is at 1.3171.
Ratios To Look Out For
It’s worth pointing out that Lyell Immunopharma Inc [NASDAQ:LYEL]’s Current Ratio is 16.19. Also, the Quick Ratio is 16.19, while the Cash Ratio stands at 4.32. Considering the valuation of this stock, the price to sales ratio is 6688.04, the price to book ratio is 0.51.
